Literature DB >> 12781045

A risk of malignancy index in preoperative diagnosis of ovarian cancer.

Shuiqing Ma1, Keng Shen, Jinghe Lang.   

Abstract

OBJECTIVE: To evaluate the ability of a risk of malignancy index (RMI), based on serum CA125 level, ultrasound findings and menopausal status, to discriminate benign from malignant pelvic mass.
METHODS: One hundred and forty women with pelvic masses, at age 30 of years or more were admitted to the Peking Union Medical College Hospital between January 1998 and June 1999. The sensitivity, specificity and positive predictive value of serum CA125 level, ultrasound findings and the menopausal status in diagnosis of ovarian cancer were evaluated separately or combined into the RMI.
RESULTS: RMI was more accurate than any individual criterion in diagnosing cancer. Using an RMI cutoff level of 200 to indicate malignancy, the RMI derived from this data set gave a sensitivity of 87.3%, a specificity of 84.4%, and a positive predictive value of 82.1%.
CONCLUSIONS: RMI is able to correctly discriminate malignant from benign pelvic mass. It can be introduced easily into clinical practice to facilitate the selection of patients for primary surgery.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12781045

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  7 in total

1.  Risk of malignancy index as an evaluation of preoperative pelvic mass.

Authors:  Zinatossadat Bouzari; Shahla Yazdani; Ziba Shirkhani Kelagar; Narges Abbaszadeh
Journal:  Caspian J Intern Med       Date:  2011

2.  Risk of malignancy index is not sensitive in detecting non-epithelial ovarian cancer and borderline ovarian tumor.

Authors:  Onur Meray; Ilgın Türkçüoğlu; Mehmet Mutlu Meydanlı; Ayşe Kafkaslı
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-03-01

3.  Is Risk Malignancy Index a Useful Tool for Predicting Malignant Ovarian Masses in Developing Countries?

Authors:  Aliya B Aziz; Nida Najmi
Journal:  Obstet Gynecol Int       Date:  2015-06-21

4.  A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.

Authors:  Santosh Kumar Dora; Atal Bihari Dandapat; Benudhar Pande; Jatindra Prasad Hota
Journal:  J Ovarian Res       Date:  2017-08-14       Impact factor: 4.234

5.  The Comparison of Pelvic Mass Score and Risk of Malignancy Index-3 in Discrimination of Benign and Malignant Adnexal Masses.

Authors:  Aliya Isgandarova; Ayse Ender Yumru; Suat Karatas; Burcu Dincgez Cakmak; Betul Dundar; Ulku Ayse Turker
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2020-12-11

6.  Investigating the clinical potential for 14-3-3 zeta protein to serve as a biomarker for epithelial ovarian cancer.

Authors:  Ioannis Hatzipetros; Peter Gocze; Tamas Koszegi; Akos Jaray; Laszlo Szereday; Beata Polgar; Nelli Farkas; Balint Farkas
Journal:  J Ovarian Res       Date:  2013-11-15       Impact factor: 4.234

7.  Discovery of specific metastasis-related N-glycan alterations in epithelial ovarian cancer based on quantitative glycomics.

Authors:  Xingwang Zhang; Yisheng Wang; Yifan Qian; Xin Wu; Zejian Zhang; Xijun Liu; Ran Zhao; Lei Zhou; Yuanyuan Ruan; Jiejie Xu; Haiou Liu; Shifang Ren; Congjian Xu; Jianxin Gu
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.